The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma
The prognostic value of CD30 expression in diffuse large B-cell lymphoma (DLBCL)remains controversial. Herein, we performed this retrospective study to investigate the clinical and prognostic significance of CD30 expression in patients with DLBCL.Among all the 146 patients, the expression of CD30 wa...
Gespeichert in:
| Veröffentlicht in: | PloS one 2015-05, Vol.10 (5), p.e0126615-e0126615 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0126615 |
|---|---|
| container_issue | 5 |
| container_start_page | e0126615 |
| container_title | PloS one |
| container_volume | 10 |
| creator | Hao, Xiaoxiao Wei, Xiaolei Huang, Fen Wei, Yongqiang Zeng, Hong Xu, Linwei Zhou, Qinjun Feng, Ru |
| description | The prognostic value of CD30 expression in diffuse large B-cell lymphoma (DLBCL)remains controversial. Herein, we performed this retrospective study to investigate the clinical and prognostic significance of CD30 expression in patients with DLBCL.Among all the 146 patients, the expression of CD30 was observed in 23 cases (15.7%).The DLBCL patients with CD30 expression showed more likely to present B symptoms, bone marrow involvement, non-germinal centre B-cell-like (Non-GCB) DLBCL, BCL-2 and Ki-67 overexpression (p |
| doi_str_mv | 10.1371/journal.pone.0126615 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1680963869</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A432104455</galeid><doaj_id>oai_doaj_org_article_85f3218f890d4804b97943b7f25ff083</doaj_id><sourcerecordid>A432104455</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-1fe2f5a3cb91735e2957a3710c25e716fa4e5783377ba8a072510ecd8d22f0943</originalsourceid><addsrcrecordid>eNqNk02P0zAQhiMEYpfCP0BgCQnBocUfcT4uSEv5qrTSSrBwtVxn3LhK4qydwPbAf2e67a5atAeUg6PxM-_Y73iS5DmjMyZy9m7tx9DpZtb7DmaU8Sxj8kFyykrBpxmn4uHB_0nyJMY1pVIUWfY4OeGyzFPG6Gny57IGAtd9gBid74i3ZP5RULLUESqCAde2Y-drFwdvamhxDRuCeOXMEInrLATnA_HjYHwLGCC9Hhx0uPnbDTWpnLVjBNLosALyYWqgaUizafvat_pp8sjqJsKz_TpJfnz-dDn_Oj2_-LKYn51PTVbyYcoscCu1MMuS5UICL2Wu0QNquIScZVanIPNCiDxf6kLTnEtGwVRFxbmlZSomycudbt_4qPbORcWygpYZelIisdgRlddr1QfX6rBRXjt1E_BhpXQYnGlAFdIKzgpblLRKC5ouyxxLLHPLpbUUTzFJ3u-rjcsWKoNmBN0ciR7vdK5WK_9LpalgBWUo8GYvEPzVCHFQ6PvWON2BH2_Ove13lklEX_2D3n-7PbXSeAFsmse6ZiuqzlK8DE1TudWa3UPhV2HfDT4z6zB-lPD2KAGZAa6HlR5jVIvv3_6fvfh5zL4-YGvQzVBH34wDvtB4DKY70AQfYwB7ZzKjajslt26o7ZSo_ZRg2ovDBt0l3Y6F-AtUoQx7</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1680963869</pqid></control><display><type>article</type><title>The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Hao, Xiaoxiao ; Wei, Xiaolei ; Huang, Fen ; Wei, Yongqiang ; Zeng, Hong ; Xu, Linwei ; Zhou, Qinjun ; Feng, Ru</creator><contributor>Batra, Surinder K.</contributor><creatorcontrib>Hao, Xiaoxiao ; Wei, Xiaolei ; Huang, Fen ; Wei, Yongqiang ; Zeng, Hong ; Xu, Linwei ; Zhou, Qinjun ; Feng, Ru ; Batra, Surinder K.</creatorcontrib><description>The prognostic value of CD30 expression in diffuse large B-cell lymphoma (DLBCL)remains controversial. Herein, we performed this retrospective study to investigate the clinical and prognostic significance of CD30 expression in patients with DLBCL.Among all the 146 patients, the expression of CD30 was observed in 23 cases (15.7%).The DLBCL patients with CD30 expression showed more likely to present B symptoms, bone marrow involvement, non-germinal centre B-cell-like (Non-GCB) DLBCL, BCL-2 and Ki-67 overexpression (p<0.05). Patients with CD30 expression showed significantly poor overall and event-free survival compared with CD30 negative patients(p = 0.031 and 0.041, respectively), especially those with the high intermediate/high-risk international prognostic index (IPI)(p = 0.001 and 0.007, respectively). The prognostic value of CD30 expression retained in DLBCL patients treated with either CHOP (cyclophosphamide, doxorubicin, vincristine,prednisone) or R-CHOP(rituximab+CHOP). The multivariate analysis revealed that the expression of CD30 remained an unfavorable factor for both overall and event-free survival (p = 0.001 and 0.002, respectively). In conclusion, these data suggest that CD30 is expressed predominantly in Non-GCBDLBCL. The expression of CD30 implied poor outcome in DLBCL patients treated with either CHOP or R-CHOP, especially those with the high intermediate/high-risk IPI, possibly indicating that anti-CD30 monoclonal antibody could be of clinical interest.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0126615</identifier><identifier>PMID: 25974110</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Analysis ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; B cells ; B-cell lymphoma ; B-Lymphocytes - metabolism ; Bcl-2 protein ; Bone marrow ; Cancer therapies ; Care and treatment ; CD30 antigen ; Chemotherapy ; Complications and side effects ; Cyclophosphamide ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - therapeutic use ; Disease-Free Survival ; Doxorubicin ; Doxorubicin - administration & dosage ; Doxorubicin - therapeutic use ; Female ; Gene expression ; Hematology ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Ki-1 Antigen - immunology ; Ki-1 Antigen - metabolism ; Ki-67 Antigen - metabolism ; Leukemia ; Lymphocytes B ; Lymphoma ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, Large B-Cell, Diffuse - mortality ; Lymphoma, Large B-Cell, Diffuse - pathology ; Male ; Medical prognosis ; Medical research ; Medicine, Experimental ; Middle Aged ; Monoclonal antibodies ; Multivariate Analysis ; Non-Hodgkin's lymphomas ; Oncology ; Patient outcomes ; Patients ; Prednisone ; Prednisone - administration & dosage ; Prednisone - therapeutic use ; Prognosis ; Proto-Oncogene Proteins c-bcl-2 - metabolism ; Retrospective Studies ; Rituximab ; Rituximab - administration & dosage ; Studies ; Targeted cancer therapy ; Treatment Outcome ; Vincristine ; Vincristine - administration & dosage ; Vincristine - therapeutic use ; Young Adult</subject><ispartof>PloS one, 2015-05, Vol.10 (5), p.e0126615-e0126615</ispartof><rights>COPYRIGHT 2015 Public Library of Science</rights><rights>2015 Hao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Hao et al 2015 Hao et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-1fe2f5a3cb91735e2957a3710c25e716fa4e5783377ba8a072510ecd8d22f0943</citedby><cites>FETCH-LOGICAL-c692t-1fe2f5a3cb91735e2957a3710c25e716fa4e5783377ba8a072510ecd8d22f0943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431801/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431801/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25974110$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Batra, Surinder K.</contributor><creatorcontrib>Hao, Xiaoxiao</creatorcontrib><creatorcontrib>Wei, Xiaolei</creatorcontrib><creatorcontrib>Huang, Fen</creatorcontrib><creatorcontrib>Wei, Yongqiang</creatorcontrib><creatorcontrib>Zeng, Hong</creatorcontrib><creatorcontrib>Xu, Linwei</creatorcontrib><creatorcontrib>Zhou, Qinjun</creatorcontrib><creatorcontrib>Feng, Ru</creatorcontrib><title>The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The prognostic value of CD30 expression in diffuse large B-cell lymphoma (DLBCL)remains controversial. Herein, we performed this retrospective study to investigate the clinical and prognostic significance of CD30 expression in patients with DLBCL.Among all the 146 patients, the expression of CD30 was observed in 23 cases (15.7%).The DLBCL patients with CD30 expression showed more likely to present B symptoms, bone marrow involvement, non-germinal centre B-cell-like (Non-GCB) DLBCL, BCL-2 and Ki-67 overexpression (p<0.05). Patients with CD30 expression showed significantly poor overall and event-free survival compared with CD30 negative patients(p = 0.031 and 0.041, respectively), especially those with the high intermediate/high-risk international prognostic index (IPI)(p = 0.001 and 0.007, respectively). The prognostic value of CD30 expression retained in DLBCL patients treated with either CHOP (cyclophosphamide, doxorubicin, vincristine,prednisone) or R-CHOP(rituximab+CHOP). The multivariate analysis revealed that the expression of CD30 remained an unfavorable factor for both overall and event-free survival (p = 0.001 and 0.002, respectively). In conclusion, these data suggest that CD30 is expressed predominantly in Non-GCBDLBCL. The expression of CD30 implied poor outcome in DLBCL patients treated with either CHOP or R-CHOP, especially those with the high intermediate/high-risk IPI, possibly indicating that anti-CD30 monoclonal antibody could be of clinical interest.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>B cells</subject><subject>B-cell lymphoma</subject><subject>B-Lymphocytes - metabolism</subject><subject>Bcl-2 protein</subject><subject>Bone marrow</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>CD30 antigen</subject><subject>Chemotherapy</subject><subject>Complications and side effects</subject><subject>Cyclophosphamide</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Disease-Free Survival</subject><subject>Doxorubicin</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - therapeutic use</subject><subject>Female</subject><subject>Gene expression</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Kaplan-Meier Estimate</subject><subject>Ki-1 Antigen - immunology</subject><subject>Ki-1 Antigen - metabolism</subject><subject>Ki-67 Antigen - metabolism</subject><subject>Leukemia</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - mortality</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Multivariate Analysis</subject><subject>Non-Hodgkin's lymphomas</subject><subject>Oncology</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Prednisone</subject><subject>Prednisone - administration & dosage</subject><subject>Prednisone - therapeutic use</subject><subject>Prognosis</subject><subject>Proto-Oncogene Proteins c-bcl-2 - metabolism</subject><subject>Retrospective Studies</subject><subject>Rituximab</subject><subject>Rituximab - administration & dosage</subject><subject>Studies</subject><subject>Targeted cancer therapy</subject><subject>Treatment Outcome</subject><subject>Vincristine</subject><subject>Vincristine - administration & dosage</subject><subject>Vincristine - therapeutic use</subject><subject>Young Adult</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk02P0zAQhiMEYpfCP0BgCQnBocUfcT4uSEv5qrTSSrBwtVxn3LhK4qydwPbAf2e67a5atAeUg6PxM-_Y73iS5DmjMyZy9m7tx9DpZtb7DmaU8Sxj8kFyykrBpxmn4uHB_0nyJMY1pVIUWfY4OeGyzFPG6Gny57IGAtd9gBid74i3ZP5RULLUESqCAde2Y-drFwdvamhxDRuCeOXMEInrLATnA_HjYHwLGCC9Hhx0uPnbDTWpnLVjBNLosALyYWqgaUizafvat_pp8sjqJsKz_TpJfnz-dDn_Oj2_-LKYn51PTVbyYcoscCu1MMuS5UICL2Wu0QNquIScZVanIPNCiDxf6kLTnEtGwVRFxbmlZSomycudbt_4qPbORcWygpYZelIisdgRlddr1QfX6rBRXjt1E_BhpXQYnGlAFdIKzgpblLRKC5ouyxxLLHPLpbUUTzFJ3u-rjcsWKoNmBN0ciR7vdK5WK_9LpalgBWUo8GYvEPzVCHFQ6PvWON2BH2_Ove13lklEX_2D3n-7PbXSeAFsmse6ZiuqzlK8DE1TudWa3UPhV2HfDT4z6zB-lPD2KAGZAa6HlR5jVIvv3_6fvfh5zL4-YGvQzVBH34wDvtB4DKY70AQfYwB7ZzKjajslt26o7ZSo_ZRg2ovDBt0l3Y6F-AtUoQx7</recordid><startdate>20150514</startdate><enddate>20150514</enddate><creator>Hao, Xiaoxiao</creator><creator>Wei, Xiaolei</creator><creator>Huang, Fen</creator><creator>Wei, Yongqiang</creator><creator>Zeng, Hong</creator><creator>Xu, Linwei</creator><creator>Zhou, Qinjun</creator><creator>Feng, Ru</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150514</creationdate><title>The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma</title><author>Hao, Xiaoxiao ; Wei, Xiaolei ; Huang, Fen ; Wei, Yongqiang ; Zeng, Hong ; Xu, Linwei ; Zhou, Qinjun ; Feng, Ru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-1fe2f5a3cb91735e2957a3710c25e716fa4e5783377ba8a072510ecd8d22f0943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>B cells</topic><topic>B-cell lymphoma</topic><topic>B-Lymphocytes - metabolism</topic><topic>Bcl-2 protein</topic><topic>Bone marrow</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>CD30 antigen</topic><topic>Chemotherapy</topic><topic>Complications and side effects</topic><topic>Cyclophosphamide</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Disease-Free Survival</topic><topic>Doxorubicin</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - therapeutic use</topic><topic>Female</topic><topic>Gene expression</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Kaplan-Meier Estimate</topic><topic>Ki-1 Antigen - immunology</topic><topic>Ki-1 Antigen - metabolism</topic><topic>Ki-67 Antigen - metabolism</topic><topic>Leukemia</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - mortality</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Multivariate Analysis</topic><topic>Non-Hodgkin's lymphomas</topic><topic>Oncology</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Prednisone</topic><topic>Prednisone - administration & dosage</topic><topic>Prednisone - therapeutic use</topic><topic>Prognosis</topic><topic>Proto-Oncogene Proteins c-bcl-2 - metabolism</topic><topic>Retrospective Studies</topic><topic>Rituximab</topic><topic>Rituximab - administration & dosage</topic><topic>Studies</topic><topic>Targeted cancer therapy</topic><topic>Treatment Outcome</topic><topic>Vincristine</topic><topic>Vincristine - administration & dosage</topic><topic>Vincristine - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hao, Xiaoxiao</creatorcontrib><creatorcontrib>Wei, Xiaolei</creatorcontrib><creatorcontrib>Huang, Fen</creatorcontrib><creatorcontrib>Wei, Yongqiang</creatorcontrib><creatorcontrib>Zeng, Hong</creatorcontrib><creatorcontrib>Xu, Linwei</creatorcontrib><creatorcontrib>Zhou, Qinjun</creatorcontrib><creatorcontrib>Feng, Ru</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hao, Xiaoxiao</au><au>Wei, Xiaolei</au><au>Huang, Fen</au><au>Wei, Yongqiang</au><au>Zeng, Hong</au><au>Xu, Linwei</au><au>Zhou, Qinjun</au><au>Feng, Ru</au><au>Batra, Surinder K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2015-05-14</date><risdate>2015</risdate><volume>10</volume><issue>5</issue><spage>e0126615</spage><epage>e0126615</epage><pages>e0126615-e0126615</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The prognostic value of CD30 expression in diffuse large B-cell lymphoma (DLBCL)remains controversial. Herein, we performed this retrospective study to investigate the clinical and prognostic significance of CD30 expression in patients with DLBCL.Among all the 146 patients, the expression of CD30 was observed in 23 cases (15.7%).The DLBCL patients with CD30 expression showed more likely to present B symptoms, bone marrow involvement, non-germinal centre B-cell-like (Non-GCB) DLBCL, BCL-2 and Ki-67 overexpression (p<0.05). Patients with CD30 expression showed significantly poor overall and event-free survival compared with CD30 negative patients(p = 0.031 and 0.041, respectively), especially those with the high intermediate/high-risk international prognostic index (IPI)(p = 0.001 and 0.007, respectively). The prognostic value of CD30 expression retained in DLBCL patients treated with either CHOP (cyclophosphamide, doxorubicin, vincristine,prednisone) or R-CHOP(rituximab+CHOP). The multivariate analysis revealed that the expression of CD30 remained an unfavorable factor for both overall and event-free survival (p = 0.001 and 0.002, respectively). In conclusion, these data suggest that CD30 is expressed predominantly in Non-GCBDLBCL. The expression of CD30 implied poor outcome in DLBCL patients treated with either CHOP or R-CHOP, especially those with the high intermediate/high-risk IPI, possibly indicating that anti-CD30 monoclonal antibody could be of clinical interest.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>25974110</pmid><doi>10.1371/journal.pone.0126615</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2015-05, Vol.10 (5), p.e0126615-e0126615 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1680963869 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Adolescent Adult Aged Aged, 80 and over Analysis Antineoplastic Combined Chemotherapy Protocols - therapeutic use B cells B-cell lymphoma B-Lymphocytes - metabolism Bcl-2 protein Bone marrow Cancer therapies Care and treatment CD30 antigen Chemotherapy Complications and side effects Cyclophosphamide Cyclophosphamide - administration & dosage Cyclophosphamide - therapeutic use Disease-Free Survival Doxorubicin Doxorubicin - administration & dosage Doxorubicin - therapeutic use Female Gene expression Hematology Humans Immunohistochemistry Kaplan-Meier Estimate Ki-1 Antigen - immunology Ki-1 Antigen - metabolism Ki-67 Antigen - metabolism Leukemia Lymphocytes B Lymphoma Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - mortality Lymphoma, Large B-Cell, Diffuse - pathology Male Medical prognosis Medical research Medicine, Experimental Middle Aged Monoclonal antibodies Multivariate Analysis Non-Hodgkin's lymphomas Oncology Patient outcomes Patients Prednisone Prednisone - administration & dosage Prednisone - therapeutic use Prognosis Proto-Oncogene Proteins c-bcl-2 - metabolism Retrospective Studies Rituximab Rituximab - administration & dosage Studies Targeted cancer therapy Treatment Outcome Vincristine Vincristine - administration & dosage Vincristine - therapeutic use Young Adult |
| title | The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T03%3A18%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20expression%20of%20CD30%20based%20on%20immunohistochemistry%20predicts%20inferior%20outcome%20in%20patients%20with%20diffuse%20large%20B-cell%20lymphoma&rft.jtitle=PloS%20one&rft.au=Hao,%20Xiaoxiao&rft.date=2015-05-14&rft.volume=10&rft.issue=5&rft.spage=e0126615&rft.epage=e0126615&rft.pages=e0126615-e0126615&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0126615&rft_dat=%3Cgale_plos_%3EA432104455%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1680963869&rft_id=info:pmid/25974110&rft_galeid=A432104455&rft_doaj_id=oai_doaj_org_article_85f3218f890d4804b97943b7f25ff083&rfr_iscdi=true |